A medical device and health services platform integrating compact ECG monitoring hardware with AI-based diagnostics. The flagship device is a TGA-approved, credit-card-sized ECG reader that connects to mobile apps for instant health profiling. The company provides both B2C and clinical B2B services, including disability and aged care partnerships under the NDIS program.
- Equity
- Targeting $54B global cardiac monitoring market
- Dual business model: device sales + clinical services
- TGA-certified hardware, strong R&D roadmap (6 patents by 2026)
- NDIS & aged care onboarding underway
- Proven revenue generation from clinical reimbursements (up to $600/session)
Problem: Cardiovascular disease is the #1 global killer; arrhythmias account for 30% of strokes. Existing tools are bulky or inaccessible.
Solution: Portable ECG devices integrated with AI diagnostics and cloud platforms; usable by clinicians and individuals at home, post-dialysis, or in rehab settings.
The global cardiac diagnostics market is expected to exceed $54.2B by 2025. Rise in chronic illness, aging population, and demand for remote monitoring post-COVID have accelerated adoption of compact, cloud-connected tools.
- Device approved by TGA (Class 2a)
- Serving both consumers & clinicians with single platform
- AI-based MapDx for disease pattern matching
- Current & future product roadmap includes wearable sensors (ECG3me, OMNIme)
- Registered NDIS provider; partnerships with aged care & disability services
- First of 6 patents to be filed in 2024
First product (ecgme) on market since Q3 2023
Revenue-generating clinical use
In development: ECG3me (3-lead clinical device, 2025)
In R&D: OMNIme graphene sensors (multi-vital signal tracking, est. 2029)
Confirmed demand from both pharmacy and fitness channels
Registered NDIS provider as of August 2024
- English
- Level 2 - Profile Verified
- Level 1 – Summary Human Translated
We’ll forward your request to the project owner and support your next step.